Jiankui He: A Sorry Tale of High-Stakes Science
By Landon J. Getz, Graham Dellaire, Francoise Baylis,
Hastings Bioethics Forum
| 12. 10. 2018
In response to news of the world’s first babies born in China from gene-edited embryos, Sam Sternberg, a CRISPR/Cas9 researcher at Columbia University, spoke for many when he said“I’ve long suspected that scientists, somewhere, would rush to claim the ‘prize’ of being first to apply CRISPR clinically to edit the DNA of human embryos, and use those embryos to establish pregnancies, but still, I’m shocked to find out it’s allegedly happened this quickly.”
There is considerable irony in Sternberg’s “shock” at the birth announcement by Jiankui He of the Southern University of Science and Technology in China, insofar as modern science (and especially frontier science) encourages competition, rewards high-performance (typically measured in terms of publications in high-impact journals, research dollars from prestigious granting agencies, lucrative patents, and promising start-ups), and celebrates “firsts” often with considerable pomp and ceremony. For chemistry, physics and physiology the most prestigious of these accolades is the Nobel Prize. As Ben Hurlbut, of Arizona State University, has remarked, He was “acting in line with” a scientific culture “that puts a premium on provocative research, celebrity...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...